27784-69-6

Basic information

• Product Name: Cyclobutylideneacetonitrile
• Synonyms: Cyclobutylideneacetonitrile
• CAS NO: 27784-69-6
• Molecular Formula: C₆H₇N
• Molecular Weight: 93.12648
• Mol File: 27784-69-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclobutylideneacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutylideneacetonitrile(27784-69-6)
• EPA Substance Registry System: Cyclobutylideneacetonitrile(27784-69-6)

Safety Data

• Hazardous Substances Data: 27784-69-6(Hazardous Substances Data)

Usage

Description

Cyclobutylideneacetonitrile, also known as CBA, is a chemical compound characterized by its molecular formula C6H9N. It is a colorless liquid with a faint, sweet odor and is recognized for its versatility as a building block in organic chemistry. CBA is primarily utilized as an intermediate in the synthesis of pharmaceuticals and other organic compounds, contributing to the creation of complex molecular structures. Its ability to undergo various chemical transformations makes it a valuable tool in organic synthesis. However, due to its toxic nature, CBA requires careful handling and adherence to proper safety protocols.

Uses

Used in Pharmaceutical Industry:
Cyclobutylideneacetonitrile is used as a synthetic intermediate for the production of various pharmaceuticals. Its role in creating complex molecular structures is crucial for the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
Cyclobutylideneacetonitrile serves as a starting material in the synthesis of a range of agrochemicals. Its chemical properties make it suitable for the development of products used in agriculture to protect crops and enhance yields.
Used in Specialty Chemicals Production:
Cyclobutylideneacetonitrile is utilized as a precursor in the manufacture of specialty chemicals, which are often used in niche applications due to their unique properties and functions.
Used in Organic Synthesis:
Cyclobutylideneacetonitrile is employed as a valuable tool in organic synthesis, where its capacity for various chemical transformations allows for the creation of a wide array of organic compounds for research and industrial applications.

Upstream product

• 1191-95-3 cyclobutanone 
• 16640-68-9 cyanomethylene triphenylphosphorane 
• 2537-48-6 diethyl 1-cyanomethylphosphonate 

Relevant articles and documents

Compounds serving as IRAK inhibitors and preparation method and application thereof

The invention belongs to the field of IRAK inhibitors, and particularly relates to compounds shown in a formula (I) and applicable to treating cancers and inflammatory diseases related to interleukin-1 receptor-associated kinase (IRAK). Experiments show t

PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES

A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.

Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof

A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.